tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Protara Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsProtara Therapeutics Reports Q1 2025 Financial Results
3M ago
Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position
Premium
Ratings
Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position
3M ago
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile
Premium
Ratings
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile
3M ago
TARA Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsTARA Upcoming Earnings Report: What to Expect?
3M ago
Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results
Premium
Ratings
Protara Therapeutics: Promising Clinical Progress and Strong Buy Rating Amid Encouraging ADVANCED-2 Study Results
3M ago
Protara Therapeutics Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Protara Therapeutics Reports Positive Phase 2 Trial Results
3M ago
Cantor starts Protara with Overweight, sees ‘multi-bagger potential’
PremiumThe FlyCantor starts Protara with Overweight, sees ‘multi-bagger potential’
5M ago
Protara Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Protara Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
Protara Therapeutics initiated with an Outperform at LifeSci Capital
Premium
The Fly
Protara Therapeutics initiated with an Outperform at LifeSci Capital
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100